Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.33 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643308 | 0.86 | ALDH1A1 (0.60) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL31258843 | 0.86 | ALDH1A1 (0.60) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL14192672 | 0.84 | ALDH1A1 (0.59) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| Hydrochloric Acid SCHEMBL4260079 | 0.84 | ALDH1A1 (0.59) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL4260072 | 0.84 | ALDH1A1 (0.59) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL15372279 | 0.82 | KDM4E (0.56) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL26054620 | 0.81 | ALDH1A1 (0.55) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL5530927 | 0.79 | MAPK8 (0.51) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL1525798 | 0.76 | ALDH1A1 (0.49) | PARP1ALDH1A1KDM4EMAPK8CXCR5 | |
| SCHEMBL6361054 | 0.76 | KDM4E (0.62) | PARP1ALDH1A1KDM4EMAPK8CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3621619-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | Arena Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2018208848-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | PARP1 3111/4885ALDH1A1 2251/4885KDM4E 4268/4885 |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | PARP1 771/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | PARP1 2775/4885ALDH1A1 603/4885KDM4E 2319/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | PARP1 771/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | PARP1 3111/4885ALDH1A1 2251/4885KDM4E 4268/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | PARP1 771/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | PARP1 771/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | PARP1 2775/4885ALDH1A1 603/4885KDM4E 2319/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | PARP1 771/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.